Drug Sponsors

Recordati finalizes acquisition of portfolio from Lundbeck

Wednesday, January 23, 2013 11:25 AM

Recordati, a specialty pharmaceutical group based in Italy, has successfully concluded the acquisition of all rights concerning a portfolio of products indicated for the treatment of rare and other diseases and marketed mainly in the U.S. from pharmaceutical company Lundbeck. The value of the transaction is of $100 million, of which $80 million were paid at the closing.

More... »

Watson acquires Uteron Pharma

Wednesday, January 23, 2013 09:30 AM

Watson Pharmaceuticals, a global, integrated specialty generics pharmaceutical company, has completed the acquisition of Belgium-based Uteron Pharma, a development-based company dedicated to female healthcare, for $150 million in cash up front, and up to $155 million in potential future milestone payments. 

More... »

Amgen to build state-of-the-art manufacturing facility in Singapore

Friday, January 18, 2013 02:49 PM

Amgen, a biotech based in Thousand Oaks, Calif., plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore.

More... »

Galapagos acquires Cangenix

Wednesday, January 16, 2013 11:21 AM

Galapagos, a mid-size clinical stage biotechnology company, has acquired Cangenix, a gene-to-structure biotech company, to add structure-based drug discovery to its Argenta service offering. Cangenix's state-of-the-art technology will augment Argenta's ability to design new drugs and fill a growing client need.

More... »

Versartis closes $25M Series C financing

Wednesday, January 16, 2013 10:24 AM

Versartis, an emerging biotechnology company focused on endocrine disorders, has completed a $25 million Series C financing lead by new investor Aisling Capital. The primary use of the proceeds will be to fund clinical trials of its lead product, VRS-317, for growth hormone deficiency (GHD) in pediatric patients. VRS-317 is a proprietary once monthly form of recombinant human growth hormone (rhGH).

More... »

Velocity Pharmaceutical announces clinical development agreement

Wednesday, January 16, 2013 09:55 AM

Velocity Pharmaceutical Development, is a pharmaceutical development organization, has signed a licensing agreement to pursue a drug development program utilizing EuMederis Pharmaceuticals' EuPort technology for optimizing the pharmaceutical properties of peptide drugs.

More... »

Catalent invests $20M to expand inhalation capabilities

Monday, January 14, 2013 12:04 PM

Catalent Pharma Solutions, Somerset, N.J.-based developer of solutions and drug delivery technology, is investing $20 million to expand its inhalation drug development, delivery and supply capabilities by enhancing its Inhalation Center of Excellence in Research Triangle Park in North Carolina. The investment will focus on expanding pressurized Metered Dose Inhaler (pMDI) clinical and commercial supply capabilities as well as other enhancements to the facility.

More... »

MorphoSys completes sale of AbD Serotec to Bio-Rad

Friday, January 11, 2013 01:55 PM

MorphoSys, a biotechnology company focusing on fully human antibodies, has completed the sale of its research and diagnostic antibody segment AbD Serotec to Waltham, Mass.-based Bio-Rad Laboratories.

More... »

Saint Luke's Hospital unveils Neuroscience Institute

Friday, January 11, 2013 11:42 AM

Designed to serve as one of the preeminent neuroscience centers in the country, the Saint Luke's Neuroscience Institute (SLNI) tower officially opened January 9 at Saint Luke's Hospital. The new facility, specializing in streamlined care for neurological disorders, offers the Kansas City community and the entire region a dedicated neuroscience hospital, created to lead the way in research, medical advancements, patient outcomes, comfort and quality of care.

More... »

Hikma to acquire the EPCI in Egypt

Friday, January 11, 2013 10:44 AM

Hikma Pharmaceuticals, a multinational pharmaceutical group, has agreed to acquire the Egyptian Company for Pharmaceuticals & Chemical Industries (EPCI) from a consortium of shareholders for an aggregate cash consideration of approximately $22.2 million.

More... »